The Drug Targeting and Delivery Across Scales Program aims to deliver antibody therapeutics across the blood-brain barrier using adeno-associated virus to target Aβ and Tau pathology. It seeks to develop mRNA therapeutics for various intracellular targets, including Tau. Additionally, the program pioneers the world’s first intravenous targeted non-viral CRISPR therapy by utilising scanning ultrasound for genome editing in the brain. Furthermore, it focuses on delivering novel anti-Tau antibodies, with and without ultrasound, to enhance functional outcomes.